Risankizumab is an effective treatment option for patients with psoriatic arthritis (PsA), according to a recent meta-analysis. Risankizumab showed superior efficacy across multiple outcomes compared ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback